David Gould
Overview
Explore the profile of David Gould including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dobres J, Chahine N, Reimer B, Gould D, Mehler B, Coughlin J
Ergonomics
. 2016 Jan;
59(10):1377-1391.
PMID: 26727912
Psychophysical research on text legibility has historically investigated factors such as size, colour and contrast, but there has been relatively little direct empirical evaluation of typographic design itself, particularly in...
12.
Subang M, Fatah R, Wu Y, Hannaman D, Rice J, Evans C, et al.
Curr Gene Ther
. 2014 Dec;
15(1):3-14.
PMID: 25545919
Immune responses to expressed foreign transgenes continue to hamper progress of gene therapy development. Translated foreign proteins with intracellular location are generally less accessible to the immune system, nevertheless they...
13.
Reimer B, Mehler B, Dobres J, Coughlin J, Matteson S, Gould D, et al.
Ergonomics
. 2014 Jul;
57(11):1643-58.
PMID: 25075429
Text-rich driver-vehicle interfaces are increasingly common in new vehicles, yet the effects of different typeface characteristics on task performance in this brief off-road based glance context remains sparsely examined. Subjects...
14.
Yeste-Velasco M, Mao X, Grose R, Kudahetti S, Lin D, Marzec J, et al.
J Pathol
. 2014 Jan;
232(5):566-77.
PMID: 24407904
Genomic changes affecting tumour suppressor genes are fundamental to cancer. We applied SNP array analysis to a panel of testicular germ cell tumours to search for novel tumour suppressor genes...
15.
16.
Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, et al.
Expert Opin Drug Deliv
. 2013 Dec;
11(1):101-10.
PMID: 24294995
Introduction: The use of cytokines as therapeutic agents is important, given their potent biological effects. However, this very potency, coupled with the pleiotropic nature and short half-life of these molecules,...
17.
Koutsokeras A, Purkayastha N, Purkayashta N, Rigby A, Subang M, Sclanders M, et al.
FASEB J
. 2013 Sep;
28(1):373-81.
PMID: 24072781
Gene therapy is a powerful approach to treat disease locally. However, if the therapeutic target is intracellular, the therapeutic will be effective only in the cells where the therapeutic gene...
18.
Pearl R, Gould D, Spiess B
Vet Ophthalmol
. 2013 Sep;
18(1):6-12.
PMID: 24025050
Objective: Two of the authors (DG, BS) independently observed that a number of Flat-Coated Retrievers (FCRs) previously unaffected by pectinate ligament dysplasia (PLD) appeared to develop the condition later in...
19.
Mullen L, Adams G, Foster J, Vessillier S, Koster M, Hauser H, et al.
Ann Rheum Dis
. 2013 Jul;
73(9):1728-36.
PMID: 23813971
Background: Latent cytokines are engineered by fusing the latency associated peptide (LAP) derived from transforming growth factor-β (TGF-β) with the therapeutic cytokine, in this case interferon-β (IFN-β), via an inflammation-specific...
20.
Viale D, Cafferata E, Gould D, Rotondaro C, Chernajovsky Y, Curiel D, et al.
J Invest Dermatol
. 2013 Apr;
133(11):2576-2584.
PMID: 23604101
We have previously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can target both the stromal and the malignant melanoma cell compartments. The replication capacity of this CRAd...